Brief Report: A Prospective Open‐Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica

Objective Interleukin‐6 (IL‐6) is a pivotal cytokine in the pathogenesis of polymyalgia rheumatica (PMR), yet the efficacy of IL‐6 blockade with tocilizumab (TCZ) for the treatment of PMR is unknown. The aim of this study was to assess the efficacy and safety of TCZ in newly diagnosed PMR. Methods....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2016-10, Vol.68 (10), p.2550-2554
Hauptverfasser:	Lally, Lindsay, Forbess, Lindsy, Hatzis, Christopher, Spiera, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Deprescriptions Female Glucocorticoids - therapeutic use Humans Hypercholesterolemia - chemically induced Immunologic Factors - therapeutic use Male Middle Aged Neutropenia - chemically induced Polymyalgia Rheumatica - drug therapy Prednisone - therapeutic use Prospective Studies Remission Induction Respiratory Tract Infections - chemically induced Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective Interleukin‐6 (IL‐6) is a pivotal cytokine in the pathogenesis of polymyalgia rheumatica (PMR), yet the efficacy of IL‐6 blockade with tocilizumab (TCZ) for the treatment of PMR is unknown. The aim of this study was to assess the efficacy and safety of TCZ in newly diagnosed PMR. Methods. In a single‐center open‐label study, patients with newly diagnosed PMR who had been treated with glucocorticoids (GCs) for
ISSN:	2326-5191 2326-5205
DOI:	10.1002/art.39740